$3.70
Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Overview
52-week range
$2.83
$16
7% of range
Avg surprise (last 2)
+3.5%
Avg reaction (last 1)
+13.8%
100% positive
Latest IV / EM
30%
EM ±6.8% · $4 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.25 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $-0.28 | $-0.29 | +3.5% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.28 | $-0.29 | +3.5% | — | +13.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.35 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.87 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.43 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.39 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.21 | -$0.28 | +25.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-22M | — | $-22M | $-20M | $-20M | — | $-25M | $52M |
| Net income | $-19M | — | $-20M | $-17M | $-18M | — | $-22M | $55M |
| EPS (diluted) | $-0.25 | — | $-0.31 | $-0.28 | $-0.28 | — | $-0.35 | $0.87 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $50M | $198M | $47M | $43M | $42M | $58M | $73M | $87M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $339M | $357M | $206M | $219M | $233M | $250M | $267M | $280M |
| Total assets | $347M | $366M | $215M | $229M | $243M | $261M | $279M | $294M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $17M | $16M | $14M | $14M | $18M | $22M | $20M |
| Total equity | $333M | $349M | $198M | $214M | $228M | $243M | $257M | $274M |